BridgeMD
New treatment option for Hematopoietic and Lymphoid System Neoplasm
Official title Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
ClinicalTrials.gov ID: NCT05893940
What this study is testing
- What it's testing
- This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a blood and/or bone marrow transplant (hematopoietic cell transplantation [HCT]) or cellular therapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)
- COHORT I: Scheduled to undergo an autologous or allogeneic HCT
- COHORT 1: \>= 18 years of age
- COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent...
- COHORT II: Diagnosis of non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic...
You likely can't join if
- COHORT 1:
- Any prior allogeneic HCT
- Any prior autologous HCT for those patients who have a planned auto HCT
- Pre-transplant weight \>= 275 lbs. (max weight for the board)
- Body mass index (BMI) \< 18 kg/m\^2
- Recipient of cord blood transplant
See the full eligibility criteria
- COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)
- COHORT I: Scheduled to undergo an autologous or allogeneic HCT
- COHORT 1: \>= 18 years of age
- COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure \- COHORT II: ≥ 18...
- COHORT II: Diagnosis of non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia; patients with preexisting osteoporosis are eligible)
- COHORT II: Patient must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- COHORT 1:
- Any prior allogeneic HCT
- Any prior autologous HCT for those patients who have a planned auto HCT
- Pre-transplant weight \>= 275 lbs. (max weight for the board)
- Body mass index (BMI) \< 18 kg/m\^2
- Recipient of cord blood transplant
- Multiple myeloma or amyloidosis diagnosis
- History of a central nervous system (CNS) hemorrhage \< 60 days
- History of any aneurysm (cerebral, aortic, etc.)
- A recent pulmonary embolism or deep vein thrombosis
- A cardiac pacemaker
- Prior history of non-traumatic (spontaneous) fracture
- Total joint replacement (any joint)
- History of kidney stones or gall stones within the last 2 years unless a cholecystectomy was performed
- Any prosthetic lower extremity or limb
- Pregnant or nursing female patients
- Unwilling or unable to follow protocol requirements
- Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study intervention COHORTII:
- Planned CAR T-cell therapy within the next 2 months
- Prior CAR T-cell therapy
- Active treatment within the last 60 days
- Pre-transplant weight ≥ 275 lbs. (max weight for the board)
- BMI \< 18 kg/m\^2
- History of a CNS hemorrhage \< 60 days
- History of any aneurysm (cerebral, aortic, etc.)
- A recent pulmonary embolism or deep vein thrombosis
- A cardiac pacemaker
- Recent history (\< 60 days) of non-traumatic (spontaneous) fracture
- Recent surgery (\< 60 days)
- Pregnant or nursing female patients
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study intervention
The study team makes the final eligibility decision.
Where it's taking place
- Buffalo, New York, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Buffalo, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.